Miao Miao

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 9

Top Topics

Acute Lymphoblastic Leukemia

Tyrosine Kinase

Top Venues

Blood cancer journal

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Xiaoxia Wu, Shenqi Lu, Xinhui Zhang, Zhen Yang, Aining Sun, Depei Wu, Huifen Zhou, Miao Miao
The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia. Cancer medicine 13 (17) (2024)
Jing Lu, Huifen Zhou, Xin Zhou, Yonggong Yang, Laigen Tong, Miao Miao, Xiaofei Yang, Suning Chen
Reduced-dose chemotherapy followed by blinatumomab in induction therapy for newly diagnosed B-cell acute lymphoblastic leukemia. Cancer medicine 13 (5) (2024)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Si-Ning Liu, Xin-Yue Zhang, Haiping Dai, Wei Cui, Jia Yin, Zheng Li, Xiao Yang, Chunxiu Yang, Sheng-Li Xue, Huiying Qiu, Miao Miao, Suning Chen, Zhengming Jin, Chengcheng Fu, Caixia Li, Aining Sun, Yue Han, Ying Wang, Lei Yu, De-Pei Wu, Qingya Cui, Xiao-Wen Tang
Which one is better for refractory/relapsed acute B-cell lymphoblastic leukemia: Single-target (CD19) or dual-target (tandem or sequential CD19/CD22) CAR T-cell therapy? Blood cancer journal 13 (1) (2023)
Limin Liu, Shunqing Wang, Erlie Jiang, Yanming Zhang, Jianyong Li, Yuewen Fu, Meiqing Lei, Kailin Xu, Mingzhen Yang, Yinghao Lu, Miao Miao, De-Pei Wu
Haploidentical vs matched sibling donor transplant for paroxysmal nocturnal haemoglobinuria: A multicenter study. Blood cancer journal 12 (6) (2022)